• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

荟萃分析中竞争风险和不同数据汇总的共享参数模型:对常见和罕见结局的影响。

Shared parameter model for competing risks and different data summaries in meta-analysis: Implications for common and rare outcomes.

机构信息

Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UK.

Department of Basic Psychology & Methodology, Faculty of Psychology, University of Murcia, Murcia, Spain.

出版信息

Res Synth Methods. 2020 Jan;11(1):91-104. doi: 10.1002/jrsm.1371. Epub 2019 Aug 22.

DOI:10.1002/jrsm.1371
PMID:31330089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7003901/
Abstract

This paper considers the problem in aggregate data meta-analysis of studies reporting multiple competing binary outcomes and of studies using different summary formats for those outcomes. For example, some may report numbers of patients with at least one of each outcome while others may report the total number of such outcomes. We develop a shared parameter model on hazard ratio scale accounting for different data summaries and competing risks. We adapt theoretical arguments from the literature to demonstrate that the models are equivalent if events are rare. We use constructed data examples and a simulation study to find an event rate threshold of approximately 0.2 above which competing risks and different data summaries may bias results if no adjustments are made. Below this threshold, simpler models may be sufficient. We recommend analysts to consider the absolute event rates and only use a simple model ignoring data types and competing risks if all of underlying events are rare (below our threshold of approximately 0.2). If one or more of the absolute event rates approaches or exceeds our informal threshold, it may be necessary to account for data types and competing risks through a shared parameter model in order to avoid biased estimates.

摘要

本文考虑了在报告多种竞争性二分类结局的研究的汇总数据分析中以及在使用不同汇总格式报告这些结局的研究中存在的问题。例如,一些研究可能报告至少有一种每种结局的患者人数,而另一些研究可能报告所有这些结局的总数。我们在风险比尺度上开发了一个共享参数模型,以考虑不同的数据汇总和竞争风险。我们从文献中的理论观点出发进行论证,如果事件很少,这些模型是等效的。我们使用构造的数据示例和模拟研究来发现一个事件率阈值,约为 0.2 以上,如果不进行调整,竞争风险和不同的数据汇总可能会产生偏差。在这个阈值以下,更简单的模型可能就足够了。我们建议分析人员考虑绝对事件率,如果所有潜在事件都很少(低于我们约 0.2 的阈值),则只考虑使用忽略数据类型和竞争风险的简单模型。如果一个或多个绝对事件率接近或超过我们的非正式阈值,则可能需要通过共享参数模型来考虑数据类型和竞争风险,以避免有偏差的估计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9125/7003901/50e50e5c6b85/JRSM-11-91-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9125/7003901/a85612be034e/JRSM-11-91-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9125/7003901/50e50e5c6b85/JRSM-11-91-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9125/7003901/a85612be034e/JRSM-11-91-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9125/7003901/50e50e5c6b85/JRSM-11-91-g002.jpg

相似文献

1
Shared parameter model for competing risks and different data summaries in meta-analysis: Implications for common and rare outcomes.荟萃分析中竞争风险和不同数据汇总的共享参数模型:对常见和罕见结局的影响。
Res Synth Methods. 2020 Jan;11(1):91-104. doi: 10.1002/jrsm.1371. Epub 2019 Aug 22.
2
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.利伐沙班与华法林或达比加群治疗非瓣膜性心房颤动患者的比较疗效
BMC Cardiovasc Disord. 2017 Sep 6;17(1):238. doi: 10.1186/s12872-017-0672-5.
3
Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.基于保险理赔数据的 18-74 岁非瓣膜性心房颤动日本患者的口服抗凝药物使用情况:一项回顾性分析。
Fam Pract. 2019 Nov 18;36(6):685-692. doi: 10.1093/fampra/cmz016.
4
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.达比加群酯两种剂量对房颤卒中和大出血的个体治疗效果评估。
Circulation. 2019 Jun 18;139(25):2846-2856. doi: 10.1161/CIRCULATIONAHA.118.035266. Epub 2019 May 3.
5
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.老年非瓣膜性心房颤动患者的口服抗凝剂比较。
J Am Geriatr Soc. 2019 Aug;67(8):1662-1671. doi: 10.1111/jgs.15956. Epub 2019 May 21.
6
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.真实世界环境中比较非维生素 K 拮抗剂口服抗凝药与维生素 K 拮抗剂预防心房颤动卒中:系统评价和荟萃分析。
Stroke. 2017 Sep;48(9):2494-2503. doi: 10.1161/STROKEAHA.117.017549. Epub 2017 Jul 17.
7
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.在大型医疗体系中比较达比加群酯和华法林在非瓣膜性心房颤动患者中的安全性和有效性。
Thromb Haemost. 2015 Nov 25;114(6):1290-8. doi: 10.1160/TH15-06-0453. Epub 2015 Oct 8.
8
The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials.非维生素 K 拮抗剂口服抗凝剂在伴有心房颤动和冠状动脉疾病的患者中的疗效和安全性:随机试验的荟萃分析。
Eur Heart J Acute Cardiovasc Care. 2019 Sep;8(6):554-561. doi: 10.1177/2048872618796990. Epub 2018 Oct 15.
9
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.口服抗凝剂在新诊断房颤老年患者中的性别特异性比较疗效
Circ Cardiovasc Qual Outcomes. 2017 Apr;10(4). doi: 10.1161/CIRCOUTCOMES.116.003418.
10
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.新型口服抗凝药治疗心房颤动患者的疗效和安全性比较:一项针对开放标签研究可能存在的偏倚进行调整的网状Meta分析
J Cardiol. 2015 Dec;66(6):466-74. doi: 10.1016/j.jjcc.2015.05.018. Epub 2015 Jul 7.

引用本文的文献

1
Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias.仅可获取汇总数据时对不相连证据网络的网状Meta分析:纳入不相连试验和单臂研究同时最小化偏倚的改良方法
Med Decis Making. 2022 Oct;42(7):906-922. doi: 10.1177/0272989X221097081. Epub 2022 May 7.
2
Response to the Letter to the Editor Regarding "Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systemic Literature Review and Network Meta-Analysis".对致编辑的信的回复,内容涉及“2%克立硼罗软膏治疗轻至中度特应性皮炎患者:系统文献综述和网状Meta分析”
Dermatol Ther (Heidelb). 2021 Dec;11(6):2241-2244. doi: 10.1007/s13555-021-00608-7. Epub 2021 Oct 10.
3

本文引用的文献

1
Using simulation studies to evaluate statistical methods.运用模拟研究评估统计方法。
Stat Med. 2019 May 20;38(11):2074-2102. doi: 10.1002/sim.8086. Epub 2019 Jan 16.
2
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.21 种抗抑郁药治疗成人重度抑郁症的急性治疗的疗效和可接受性比较:系统评价和网络荟萃分析。
Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.
3
Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities.
Multilevel and Quasi Monte Carlo Methods for the Calculation of the Expected Value of Partial Perfect Information.多层次和拟蒙特卡罗方法在部分完全信息期望值计算中的应用。
Med Decis Making. 2022 Feb;42(2):168-181. doi: 10.1177/0272989X211026305. Epub 2021 Jul 7.
4
Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.西利珠单抗与对照药物治疗成人镰状细胞病的系统评价和网络荟萃分析。
BMJ Open. 2020 Sep 17;10(9):e034147. doi: 10.1136/bmjopen-2019-034147.
不同建模严重低血糖事件的方法:对有效性、成本和健康效用的影响。
Pharmacoeconomics. 2018 May;36(5):523-532. doi: 10.1007/s40273-018-0612-y.
4
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.口服抗凝药预防心房颤动患者卒中:系统评价、网状Meta分析及成本效益分析
BMJ. 2017 Nov 28;359:j5058. doi: 10.1136/bmj.j5058.
5
Assessing meta-regression methods for examining moderator relationships with dependent effect sizes: A Monte Carlo simulation.评估元回归方法以检验与依存效应大小的调节关系:一项蒙特卡罗模拟。
Res Synth Methods. 2017 Dec;8(4):435-450. doi: 10.1002/jrsm.1245. Epub 2017 May 28.
6
Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.口服抗凝剂用于静脉血栓栓塞性疾病的一级预防、治疗和二级预防,以及用于心房颤动的卒中预防:系统评价、网状荟萃分析和成本效益分析。
Health Technol Assess. 2017 Mar;21(9):1-386. doi: 10.3310/hta21090.
7
Introduction to the Analysis of Survival Data in the Presence of Competing Risks.存在竞争风险时生存数据的分析导论
Circulation. 2016 Feb 9;133(6):601-9. doi: 10.1161/CIRCULATIONAHA.115.017719.
8
Meta-analysis for aggregated survival data with competing risks: a parametric approach using cumulative incidence functions.具有竞争风险的汇总生存数据的Meta分析:一种使用累积发病率函数的参数方法。
Res Synth Methods. 2016 Sep;7(3):282-93. doi: 10.1002/jrsm.1165. Epub 2015 Sep 20.
9
Multivariate meta-analysis using individual participant data.使用个体参与者数据的多变量荟萃分析。
Res Synth Methods. 2015 Jun;6(2):157-74. doi: 10.1002/jrsm.1129. Epub 2014 Nov 21.
10
Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies.癌症疗法卫生技术评估中生存和疾病进展结局的综合评价。
Res Synth Methods. 2010 Jul;1(3-4):239-57. doi: 10.1002/jrsm.21. Epub 2011 Mar 4.